The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice

被引:64
作者
McHutchison, JG
Bartenschlager, R
Patel, K
Pawlotsky, JM
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Gastroenterol, Durham, NC 27707 USA
[2] Heidelberg Univ, Dept Mol Virol, Heidelberg, Germany
[3] Univ Paris 12, Hop Henri Mondor, Dept Virol, F-94010 Creteil, France
[4] Univ Paris 12, Hop Henri Mondor, INSERM, U635, F-94010 Creteil, France
关键词
D O I
10.1016/j.jhep.2005.12.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:411 / 421
页数:11
相关论文
共 57 条
[11]   Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease [J].
Foy, E ;
Li, K ;
Wang, CF ;
Sumpter, R ;
Ikeda, M ;
Lemon, SM ;
Gale, M .
SCIENCE, 2003, 300 (5622) :1145-1148
[12]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[13]   L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus [J].
Gardner, JP ;
Durso, RJ ;
Arrigale, RR ;
Donovan, GP ;
Maddon, PJ ;
Dragic, T ;
Olson, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4498-4503
[14]  
Gish RG, 2005, J HEPATOL, V42, P39
[15]   Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients [J].
Hinrichsen, H ;
Benhamou, Y ;
Wedemeyer, H ;
Reiser, M ;
Sentjens, RE ;
Calleja, JL ;
Forns, X ;
Erhardt, A ;
Crönlein, J ;
Chaves, RL ;
Yong, CL ;
Nehmiz, G ;
Steinmann, GG .
GASTROENTEROLOGY, 2004, 127 (05) :1347-1355
[16]   Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection [J].
Horsmans, Y ;
Berg, T ;
Desager, JP ;
Mueller, T ;
Schott, E ;
Fletcher, SP ;
Steffy, KR ;
Bauman, LA ;
Kerr, BM ;
Averett, DR .
HEPATOLOGY, 2005, 42 (03) :724-731
[17]   Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles [J].
Hsu, M ;
Zhang, J ;
Flint, M ;
Logvinoff, C ;
Cheng-Mayer, C ;
Rice, CM ;
McKeating, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (12) :7271-7276
[18]   Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons [J].
Jarczak, D ;
Korf, M ;
Beger, C ;
Manns, MP ;
Krüger, M .
FEBS JOURNAL, 2005, 272 (22) :5910-5922
[19]   Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon [J].
Kato, T ;
Date, T ;
Miyamoto, M ;
Furusaka, A ;
Tokushige, K ;
Mizokami, M ;
Wakita, T .
GASTROENTEROLOGY, 2003, 125 (06) :1808-1817
[20]   An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus [J].
Lamarre, D ;
Anderson, PC ;
Bailey, M ;
Beaulieu, P ;
Bolger, G ;
Bonneau, P ;
Bös, M ;
Cameron, DR ;
Cartier, M ;
Cordingley, MG ;
Faucher, AM ;
Goudreau, N ;
Kawai, SH ;
Kukolj, G ;
Lagacé, L ;
LaPlante, SR ;
Narjes, H ;
Poupart, MA ;
Rancourt, J ;
Sentjens, RE ;
St George, R ;
Simoneau, B ;
Steinmann, G ;
Thibeault, D ;
Tsantrizos, YS ;
Weldon, SM ;
Yong, CL ;
Llinàs-Brunet, M .
NATURE, 2003, 426 (6963) :186-189